A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
9608
Patient-Derived Stem Cell Therapies, Spinal Cord Injury, Multiple Sclerosis, Parkinson’s Disease.
Regenerative Medicine, Neurology. Company has developed patient-derived, adult stem cell based therapies for the treatment of neurological damage from spinal cord injury, thereby circumventing the […]
Acadia and Biovail Not Giving Up on Parkinson’s Drug
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
Fall Allergy Season Is Upon Us
Ragweed season is under way, bringing with it sneezes, sniffles, and itchy eyes for 36 million Americans.